These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 27615724)

  • 1. Pre-exposure prophylaxis: a useful tool to prevent human immunodeficiency virus infection?
    Pialoux G; Delaugerre C; Cotte L; Raffi F; Cua E; Molina JM
    Clin Microbiol Infect; 2016 Sep; 22(9):757-767. PubMed ID: 27615724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre-Exposure Prophylaxis for HIV Prevention: Safety Concerns.
    Tetteh RA; Yankey BA; Nartey ET; Lartey M; Leufkens HG; Dodoo AN
    Drug Saf; 2017 Apr; 40(4):273-283. PubMed ID: 28130774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The future of pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) infection.
    Özdener AE; Park TE; Kalabalik J; Gupta R
    Expert Rev Anti Infect Ther; 2017 May; 15(5):467-481. PubMed ID: 28322067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Considerations regarding antiretroviral chemoprophylaxis in MSM.
    Poynten IM; Zablotska I; Grulich AE
    Curr Opin HIV AIDS; 2012 Nov; 7(6):549-56. PubMed ID: 22918448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are current guidelines adapted for patient eligibility to PrEP? A case report.
    Van Obberghen EK; Viard D; Lafeuillade A; Civiletti A; Rocher F; Drici MD
    BMC Infect Dis; 2019 Jul; 19(1):601. PubMed ID: 31291899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: current considerations in light of new findings.
    Myers GM; Mayer KH
    AIDS Patient Care STDS; 2011 Feb; 25(2):63-71. PubMed ID: 21284497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Animal models of antiretroviral prophylaxis for HIV prevention.
    García-Lerma JG; Heneine W
    Curr Opin HIV AIDS; 2012 Nov; 7(6):505-13. PubMed ID: 22964889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug Resistance During HIV Pre-Exposure Prophylaxis.
    Gibas KM; van den Berg P; Powell VE; Krakower DS
    Drugs; 2019 Apr; 79(6):609-619. PubMed ID: 30963509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimating efficacy in a randomized trial with product nonadherence: application of multiple methods to a trial of preexposure prophylaxis for HIV prevention.
    Murnane PM; Brown ER; Donnell D; Coley RY; Mugo N; Mujugira A; Celum C; Baeten JM;
    Am J Epidemiol; 2015 Nov; 182(10):848-56. PubMed ID: 26487343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pre-exposure prophylaxis (PrEP) for men who have sex with men in Europe: review of evidence for a much needed prevention tool.
    Reyniers T; Hoornenborg E; Vuylsteke B; Wouters K; Laga M
    Sex Transm Infect; 2017 Aug; 93(5):363-367. PubMed ID: 27872326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current concepts for PrEP adherence in the PrEP revolution: from clinical trials to routine practice.
    Haberer JE
    Curr Opin HIV AIDS; 2016 Jan; 11(1):10-7. PubMed ID: 26633638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-exposure prophylaxis (PrEP) in HIV-uninfected individuals with high-risk behaviour.
    Nadery S; Geerlings SE
    Neth J Med; 2013; 71(6):295-9. PubMed ID: 23956310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV Infection and Drug Resistance with Unsupervised Use of HIV Pre-Exposure Prophylaxis.
    Volk JE; Nguyen DP; Hare CB; Marcus JL
    AIDS Res Hum Retroviruses; 2018 Apr; 34(4):329-330. PubMed ID: 29262689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis B virus reactivation or reinfection in a FEM-PrEP participant: a case report.
    Malahleha M; Ahmed K; Deese J; Nanda K; van Damme L; De Baetselier I; Burnett RJ
    J Med Case Rep; 2015 Sep; 9():207. PubMed ID: 26411737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pre-exposure prophylaxis for human immunodeficiency virus: the past, present, and future.
    Castel AD; Magnus M; Greenberg AE
    Infect Dis Clin North Am; 2014 Dec; 28(4):563-83. PubMed ID: 25455314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acceptability of an "on-demand" pre-exposure HIV prophylaxis trial among men who have sex with men living in France.
    Lorente N; Fugon L; Carrieri MP; Andreo C; Le Gall JM; Cook E; Aboulker JP; Capitant C; Molina JM; Spire B
    AIDS Care; 2012; 24(4):468-77. PubMed ID: 22085083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preexposure Prophylaxis (PrEP) for HIV Prevention: The Primary Care Perspective.
    Conniff J; Evensen A
    J Am Board Fam Med; 2016; 29(1):143-51. PubMed ID: 26769887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pre-exposure prophylaxis (PrEP) against HIV: efficacy, safety and uncertainties.
    Sanchez Conde M; Vivancos Gallego MJ; Moreno Guillen S
    Farm Hosp; 2017 Sep; 41(5):630-637. PubMed ID: 28847253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The risk of HIV drug resistance following implementation of pre-exposure prophylaxis.
    van de Vijver DA; Boucher CA
    Curr Opin Infect Dis; 2010 Dec; 23(6):621-7. PubMed ID: 20847692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Taiwan guideline on oral pre-exposure prophylaxis for HIV prevention - 2018 update.
    Yen-Hao Chu I; Wen-Wei Ku S; Li CW; Toh HS; Yang CJ; Wu KS; Wu HJ; Chen SS; Kuo JH; Lin HH; Ko NY
    J Microbiol Immunol Infect; 2020 Feb; 53(1):1-10. PubMed ID: 31628087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.